OpenEvidence just closed a massive $200 million Series C at a $6 billion valuation, nearly doubling its worth in just three months. The medical AI platform, which doctors call 'ChatGPT for medicine,' is riding unprecedented investor appetite for specialized AI applications as healthcare professionals embrace AI-powered clinical decision support tools.
OpenEvidence is rewriting the rules of medical AI funding. The startup just secured $200 million at a staggering $6 billion valuation, according to The New York Times, marking one of the fastest valuation jumps in healthcare AI history.
The numbers tell a remarkable growth story. Just three months ago, OpenEvidence closed a $210 million round at $3.5 billion - meaning the company's worth has skyrocketed 71% in a single quarter. That kind of acceleration is virtually unheard of outside the hottest consumer AI plays, yet here's a B2B medical platform pulling OpenAI-level investor excitement.
Google Ventures led the round with a who's who of Silicon Valley's most selective firms joining in: Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft Ventures. When this caliber of investors pile into a single round, it signals something fundamental is shifting in the market.
What's driving the frenzy isn't just hype - it's usage that's exploding in real-time. OpenEvidence now processes 15 million clinical consultations monthly, nearly double the volume from July. That's roughly 500,000 medical queries every single day flowing through their platform, each one representing a doctor or nurse seeking AI-powered insights to help treat patients.
The platform's secret sauce lies in its training data and business model. Built on medical journals from JAMA and the New England Journal of Medicine, OpenEvidence gives healthcare professionals instant access to evidence-based medicine through a ChatGPT-style interface. But unlike consumer AI tools, this platform requires verified medical credentials to access - creating a trusted environment for clinical decision support.
Even more intriguing is how OpenEvidence makes money. The platform is completely free for verified medical professionals, supported entirely by advertising revenue. It's a bold bet that mirrors Google's original search strategy - give away the product, monetize the attention. In healthcare, where professionals are notoriously price-sensitive and skeptical of new tools, this approach is proving genius.
The timing couldn't be better for specialized AI applications. While general-purpose models like ChatGPT grab headlines, investors are increasingly betting on vertical AI solutions that solve specific industry problems. Healthcare represents the ultimate vertical - massive market, clear use cases, and professionals desperate for better tools to manage information overload.
Founded just three years ago in 2022, OpenEvidence's trajectory mirrors the broader medical AI boom. The company's growth coincides with healthcare systems worldwide grappling with physician shortages, burnout, and the need to process ever-expanding medical literature. When doctors can get instant, evidence-based answers to clinical questions, it fundamentally changes how they practice medicine.
The competitive landscape is heating up fast. Microsoft is pushing healthcare AI through its partnership with Epic Systems, while Amazon is building AWS HealthLake for medical data. But OpenEvidence's focus on front-line clinical decision support gives it a unique position in the ecosystem.
What sets this funding apart is the speed and scale. Most healthcare AI startups take years to reach billion-dollar valuations, but OpenEvidence is scaling at consumer internet speeds while solving enterprise healthcare problems. That combination is exactly what VCs are hunting for in today's AI market.
OpenEvidence's meteoric rise signals a fundamental shift in how healthcare professionals embrace AI tools. With 15 million monthly consultations and backing from Silicon Valley's top investors, the company is positioned to become the definitive AI assistant for medical decision-making. The real test will be whether this growth can sustain as competition intensifies and regulatory scrutiny increases around AI in healthcare.
